Register for free to
view the full innovation profile.
Can predict among cognitive normal who will progress to disease, minimally-invasive (as opposed to lumbar puncture) and low cost (low tech, as opposed to neuroimaging.
About
Description Dr. Federoff and his team have discovered several biomarkers including but not limited to lipids, metabolites, genes and proteins in the blood that can predict with close to 100% accuracy if a healthy person will develop mild cognitive impairment or Alzheimer’s disease (AD). Existing preclinical biomarkers of AD are obtained either through time-consuming and expensive neuroimaging modalities, or via invasive and risky lumbar punctures for cerebrospinal fluid analyses. The present invention has a potential for a powerful blood test to identify people at risk for progressive cognitive decline. Further, the novel method has a potential to be used in selecting individuals for secondary prevention trials and to provide clues for targeted therapeutic interventions. Applications May be a useful clinical indicator of stage of disease, biomarkers can be used to differentiate AD from Frontotemporal Dementia. The technology can accurately identify people at risk for progressive cognitive decline, and be of value in terms of having the individuals, their families and treating physicians plan for and manage the disorder. The technology can be potentially be used for developing treatment strategies for Alzheimer’s at an earlier stage, when therapy would be more effective at slowing or preventing onset of symptoms. They may be used for identifying patients for secondary prevention trials.